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Abstract
Introduction Genetic associations of American sarcoidosis
susceptibility implicate MHC class II allele, DRB1*1101.
We previously reported immune recognition of Mycobac-
terium peptides from peripheral cells of 26 sarcoidosis
subjects, 24 PPD− healthy volunteers, and eight with latent
tuberculosis infection.
Materials and Methods In order to further link these
genetic and immunologic pillars of sarcoidosis pathogene-
sis, we performed flow cytometry on these same subjects
to identify the cells responsible for immune responses to
ESAT-6 and katG peptides, followed by HLA typing to
determine allelic associations with recognition.
Discussion and Conclusion Sarcoidosis CD4+ T cells were
primarily responsible for the systemic responses. Recognition
was inhibited by monoclonal antibody against HLA-DR and
HLA-DQ, but not HLA-DP. Immune recognition of ESAT-6
peptide NNALQNLARTISEAG was associated with posses-
sion of DRB1*1101. ESAT-6 and katG presented by antigen-
presenting cells expressing DRB1*1101-induced Th-1
responsesfromsarcoidosisTcells,thusprovidingamechanistic
insight for the association of HLA DRB1*1101 with sarcoid-
osis, and sarcoidosis Tcell interaction with microbial antigens.
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Studies of T cell receptor gene expression in sarcoidosis
subjects reveal oligoclonal collections of αβ
+ CD4+ T
cells, consistent with a MHC-restricted antigen-driven
process [1–3]. This complex of antigen presented by
MHC class II alleles is recognized by antigen-specific T
cells, leading to the production of IL-2 and interferon
gamma [IFN-γ][ 4]. Considerable evidence indicates that
CD4+ T cells are important in the immunopathogenesis of
sarcoidosis, and the development of granulomatous inflam-
mation in the lung is associated with the accumulation of
CD4+ T cells [5]. In the presence of antigen-presenting
cells expressing MHC class II molecules, these T cells can
be shown to proliferate and release Th-1 cytokines [5].
Certain HLA class II alleles have been associated with
sarcoidosis outcome. HLA-DRB1*03 (previously DR3 or
DR17) is strongly associated with symptoms found in acute
sarcoidosis, and these features are linked to a favorable
disease course [6–8]. Almost every DRB1*03-positive
patient had a resolving disease within 2 years, and 50% of
the DRB1*03-negative patients developed a non-resolving
disease. In line with the association between DRB1*03 and
the disease course was the finding of a significantly higher
incidence of positive biopsies in the DRB1*03-negative
patients, indicating a more widespread granuloma forma-
tion in these patients [8]. A more recent finding is that a
particular CCR2 haplotype seems to associate, indepen-
dently of DRB1*03, with Lofgren’s syndrome [9]. In
American sarcoidosis subjects, the HLA-DRB1*1101 allele
was associated (P≤0.01) with sarcoidosis in blacks and
whites and had a population attributable risk of 16% in
blacks and 9% in whites [10]. Among Polish sarcoidosis
subjects, DRB1*11 has been associated with increased risk
[11].
Recent studies have identified humoral and cellular
immune responses to mycobacterial antigens among sar-
coidosis subjects worldwide [12–14]. We recently reported
cellular immune responses to mycobacterial virulence
factors, ESAT-6 and katG among 15/26 sarcoidosis,
compared to 1/24 PPD-negative (PPD−) and 7/8 PPD-
positive (PPD+) subjects, due to latent tuberculosis using
the enzyme-linked immunospot (ELISPOT) assays [13].
How the sarcoid antigen-specific CD4+ Tcells interact with
the MHC/mycobacteria peptide complex and the role of
disease susceptible alleles in antigen presentation is
currently unknown.
Epidemiologic evidence from sarcoidosis studies in
multiple ethnic and racial groups suggests that HLA-DR
and -DQ types confer risk or protection [10, 15, 16]. HLA-
DRB1*1101 has been reported as an independent risk
factor for disease among African American and Caucasian
sarcoidosis subjects [10]. Since the ability to develop a
CD4+ T cell response in sarcoidosis depends on immuno-
genic peptides binding to HLA class II molecules, the
primary aim of this study is to provide mechanistic insight
into the genetic association of HLA DRB1*1101 with
sarcoidosis susceptibility and the immunologic observation
of Th-1 sarcoidosis immune responses to mycobacterial
antigens. Using flow cytometry, we determined that CD4+
T cells were primarily responsible for the systemic
sarcoidosis immune responses. In addition, we performed
MHC class II typing on all study participants and
discovered an association with immune responses to
mycobacterial virulence factors and possession of the allele,
HLA DRB1*1101.
Methods
Study Population This study was approved by the Vander-
bilt University Institutional Review Board for human
studies. Informed written consent was obtained from the
study participant or their surrogates. All sarcoidosis
subjects from the available patient database of the Vander-
bilt University Pulmonary Clinic were invited to participate
in the study. All patients came from the southeastern United
States. For inclusion in this study, the clinical, histologic,
and microbiologic criteria used to define sarcoidosis
patients were as previously described [17]. Healthy PPD−
volunteers must have undergone PPD testing by the
Vanderbilt employee health services. PPD-positive subjects
had written documentation of their PPD status, and had no
evidence of active disease at the time of study enrollment.
Sarcoidosis subjects underwent tuberculin skin testing at
the discretion of their physician. Each sarcoidosis subject
underwent a chart review to investigate the site of
involvement by sarcoidosis. The demographic information
of the study participants is listed in Table I.
Peptide Synthesis and Preparation of Peripheral Blood
Mononuclear Cells (PBMC) The ESAT-6 and katG pep-
tides were synthesized as previously described [13]. The
sequence for ESAT-6 peptide 14 is NNALQNLARTI-
SEAG. The sequence for katG peptide 13 is
WTNTPTKWDNSFLEI. The preparation of PBMC also
was as previously described [13].
Enzyme-Linked Immunospot Assay ELISPOT assays were
performed as previously described [18]. The number of
specific gamma interferon-secreting T cells was calculated
by subtracting the mean negative control value from the
mean spot-forming-cell (SFC) count for duplicate wells
inoculated with peptide. Negative controls always had <50
SFC per 10
6 input cells. A positive response was defined as
a concentration of at least 50 SFC/10
6 PBMC that is at least
158 J Clin Immunol (2010) 30:157–166Table I Immune Recognition and HLA-DR and HLA-DQ Type of Study Participants
Age
a/race
b/sex
c HLA type class II DR HLA type class II DQ katG
d ESAT-6
d
Sarcoidosis 1 58AAF DRB1 0701/1101 DQB1 0301/0303 580 100
Sarcoidosis 2 53AAM DRB1 08/12 DQB1 0402/0501 480 320
Sarcoidosis 3 50CM DRB1 1001/1201 DQB1 0501/0301 300 550
Sarcoidosis 4 55CF DRB1 1101/1501 DRB3 0202 DRB5 0101 DQB1 0301/0602 300 280
Sarcoidosis 5 52AAF DRB1 1302/1503 DRB3 0301 DRB5 0202 DQB1 0602/0609 110 500
Sarcoidosis 6 50AAM DRB1 1101/1501 DRB3 0202 DRB5 0101 DQB1 0602 90 130
Sarcoidosis 7 58AAM DRB1 0701/1401 DQB1 0202/0503 510 <50
Sarcoidosis 8 52AAF DRB1 0103/0701 DQB1 0303/0501 500 <50
Sarcoidosis 9 40CM DRB1 0701/1301 DRB3 0202 DQB1 0303/0603 <50 590
Sarcoidosis 10 33CF DRB1 0101/1501 DQB1 0501/0602 420 <50
Sarcoidosis 11 51CF DRB1 0701/1101 DQB1 0301/0303 370 <50
Sarcoidosis 12 31AAM DRB1 0302/0804 DRB3 0101 DQB1 0301/0402 240 <50
Sarcoidosis 13 33CF DRB1 0301/1101 DQB1 0301/09 <50 100
Sarcoidosis 14 46AAM DRB1 0701/1201 DQB1 0202/0501 120 <50
Sarcoidosis 15 62CM DRB1 0404/1501 DBR5 0101 DQB1 0302/0602 110 <50
Sarcoidosis 16 47CF DRB1 0401/1101 DQB1 0301 <50 <50
Sarcoidosis 17 51AAF DRB1 1101/1303 DRB3 0202 DQB1 0201/0602 <50 <50
Sarcoidosis 18 42AAF DRB1 7/15 <50 <50
Sarcoidosis 19 49AAF DRB1 1201/1503 DRB3 0101 DRB5 0101 DQB1 0501/0602 <50 <50
Sarcoidosis 20 22CM DRB1 1301 DRB3 0202 DQB1 0603 <50 <50
Sarcoidosis 21 41CF DRB1 0101/1302 DQB1 0501/0609 <50 <50
Sarcoidosis 22 47AAM DRB1 0804/1301 DRB3 0101 DQB1 0501/0603 <50 <50
Sarcoidosis 23 47CF DRB1 0101/1302 DRB3 0301 DQB1 0501/0604 <50 <50
Sarcoidosis 24 51CF DRB1 0401/0701 DQB1 0201/0301 <50 <50
Sarcoidosis 25 37CM DRB1 1301/1501 DRB3 0101 DRB5 0101 DQB1 0602/0603 <50 <50
Sarcoidosis 26 61CF DRB1 1302/1501 DRB3 0301 DRB5 0101 DQB1 0602/0604 <50 <50
Control 1 36AAF DRB1 0701/1101 DQB1 0303/0301 <50 380
Control 2 37CM DRB1 1101/1501 DQB1 0301/ 0602 <50 <50
Control 3 23CM DRB1 0401/1101 DRB3 0202 DQB1 0301 <50 <50
Control 4 58CF DRB1 0301/1201 DRB3 0202 DQB1 0201/0301 <50 <50
Control 5 25CF DRB1 1201/1302 DRB3 0202/0301 DQB1 0301/0609 <50 <50
Control 6 30CM DRB1 0301 DQB1 0201 <50 <50
Control 7 27AAM DRB1 0701/1401 DQB1 0201/ 0503 <50 <50
Control 8 33CF DRB1 15/08 DBQ1 0301/0609 <50 <50
Control 9 31CM DRB1 0103/0701 DQB1 0201/0301 <50 <50
Control 10 31CF DRB1 15/08 DQB1 0301/0602 <50 <50
Control 11 25HM DRB1 0701/1501 DRB5 0101 DQB1 0202/0602 <50 <50
Control 12 32CM DRB1 0401/1501 DRB5 0101 DQB1 0302/0602 <50 <50
Control 13 24CF DRB1 0401/1501 DRB5 0101 DQB1 0301/0602 <50 <50
Control 14 37CF DRB1 0301 DRB3 0101 DQB1 0201 <50 <50
Control 15 27AAF DRB1 0701/1401 DRB3 0202 DQB1 0201/0503 <50 <50
Control 16 33AAF DRB1 0301/0701 DRB3 0202 DQB1 0201 <50 <50
Control 17 33CF DRB1 1301/1501 DQB1 0602/ 0611 <50 <50
Control 18 31AAM DRB1 0301/0302 DRB3 0101/0202 DQB1 0201/0402 <50 <50
Control 19 51CF DRB1 0404/1501 DRB5 0101 DQB1 0302/0602 <50 <50
Control 20 35CF DRB1 0301/1302 DRB3 0101/0301 DQB1 0201/0604 <50 <50
Control 21 34AAF DRB1 0701/1302 DRB3 0301 DQB1 0501/0201 <50 <50
Control 22 34CM DRB1 0701/1401 DRB3 0202 DQB1 0201/0503 <50 <50
Control 23 37AAF DRB1 0405/1503 DRB5 0101 DQB1 0302/0602 <50 <50
J Clin Immunol (2010) 30:157–166 159three times higher than the background level. The research
assistants were blind to the clinical diagnoses of the study
participants throughout the analysis.
HLA II Typing Typing was performed at Dialysis Clinical
Incorporated (Nashville, TN), which provides HLA typing
for organ transplantion at Vanderbilt University Medical
Center. The samples were typed for HLA-DRB1, DRB3,
DRB5, and DQB1 using LabType (One Lambda) reverse
Sequence-specific oligonucleotide probes (SSOP) and
utilizing Luminex technology. Internal controls were
included according to the guidelines of the American
Society of Histocompatibility and Immunogenetics. Ge-
nomic DNA was first amplified using polymerase chain
reaction (PCR) with a group-specific primer for each locus,
biotinylated and detected using R-phycoerythrin-conjugated
strepavidin (SAPE). Following denaturation and re-
hybridization to complementary DNA probes conjugated
to fluorescently coded microspheres, the bead/PCR prod-
ucts were detected with SAPE. A flow analyzer, the
LABScan 100, identified the fluorescent intensity of
phycoerythrin (PE) on each microsphere. The assignment
of HLA typing was based on the reaction pattern compared
to with published HLA sequences. Analysis was performed
using One Lambda software. Peptide binding assays to
assess binding affinity of mycobacterial peptides with MHC
class II alleles were performed at La Jolla Institute for
Allergy and Immunology, La Jolla, CA by Dr. Alex Sette as
previously described [19].
Cell Isolation and Culture The media used in all experi-
ments was RPMI 1640 (cellgro) supplemented with 10%
fetal bovine serum (FBS; Gemini Bio-Products), penicillin
(50 U/ml; cellgro), streptomycin (50 ug/ml; cellgro),
sodium pyruvate (1 mM; cellgro), and glutamine (2 mM;
cellgro). To generate allogeneic dendritic cells (DCs),
CD14
+ monocytes were purified from Sarcoidosis 6 PBMC
using the MACS® system (Miltenyi Biotec) and cultured in
the presence of IL-4 (100 ng/ml) and GM-CSF (50 ng/ml;
both from R&D Systems) for 4–6 days. DCs were then
matured by the addition of lipopolysaccharide (LPS)
overnight. PBMC were isolated from sarcoidosis subject 6
and were activated with autogenic (self-derived) DCs and
either ESAT-6 or katG peptides. The activated PBMC were
then cultured in IL-2 containing medium for approximately
21 days.
Class II HLA Restriction Analysis by Intracellular Cytokine
Staining of T Cells To identify IFN-γ and IL-2-secreting T
cells in response to ESAT-6, staining with a combination of
T cell surface markers and intracellular staining was
performed as previously described [20]. Briefly, 0.5–1.0×
10
6 PBMC were incubated with 10 μM ESAT-6 and the anti-
CD28 and anti-CD49d mAbs (1 μg/ml each; BD Bioscien-
ces) at 37°C under 5% CO2 for 2 h before addition of 10 μg
of brefeldin A (Sigma)/ml. Following a 13-h incubation at
37°C under 5% CO2, cells were washed and stained with the
surface antibodies anti-CD8+ and anti-CD4+ (BD Bioscien-
ces) at 4°C for 30 min. After washing, fixation, and
permeabilization using Fix&Perm Kit according to the
manufacturer’s instructions (Caltag, Burlingame, CA), anti-
IFN-γ mAb (BD Biosciences) was added at 4°C for 30 min.
The lymphocyte population was identified using forward and
90° light-scatter patterns, and fluorescence intensity was
analyzed using a LSR II Multiparameter Cytometer (BD
Biosciences Immunocytometry Systems). The presenting
MHC class II molecules were determined by the addition
of monoclonal antibodies (mAb) against HLA-DR, HLA-DP
or HLA-DQ (BD Biosciences) at a concentration of 3 μg/ml
1 h prior to the addition of the ESAT-6 to 0.5–1.0×10
6
Table I (continued)
Age
a/race
b/sex
c HLA type class II DR HLA type class II DQ katG
d ESAT-6
d
Control 24 32AAF DRB1 0701/0901 DQB1 0201/0303 <50 <50
PPD+ 1 45CF DRB1 0403/1101 DQB1 0301/0302 400 500
PPD+ 2 41AAF DRB1 1101 DRB3 0202 DQB1 0501/0602 750 230
PPD+ 3 34CF DRB1 0101/0301 DQB1 0201/0501 430 400
PPD+ 4 57AAM DRB10701/1001 DQB1 0202/0501 60 500
PPD+ 5 49CF DRB1 0404/1001 DQB1 0501 0302 280 <50
PPD+ 6 63CF DRB1 1501 DQB1 0501/ 0602 180 <50
PPD+ 7 64CF DRB1 1303/1401 DQB1 0301/0503 80 <50
PPD+ 8 49CF DRB1 0301 DQB1 0201 <50 <50
aAge in years
bAA African American, A African, C Caucasian, H Hispanic, I Asian Indian
cF female, M male
dInteferon-γ producing spot-forming units per million PBMC
160 J Clin Immunol (2010) 30:157–166PBMC. The experiment was then conducted as described
above.
Immune Recognition with DRB1*1101, DRB3*0202
Transformed Cell Line Sweig cells are Epstein–Barr virus-
immortalized lymphocyte cell lines (EBV-immortalized
LCLs), derived by infecting adult B cells with the B958
strain. They were obtained as a generous gift of Janice
Blum (Indiana University Purdue University Institute). The
Sweig cells express HLA DRB1*1101 and DRB3*0202.
Using the Sweig cells for antigen presentation, immune
recognition of ESAT-6 and katG peptides were analyzed
from the expanded cell lines for intracellular cytokine
production of IFN-γ by flow cytometry. Cells stimulated by
staphylococcal enterotoxin B (SEB) served as the positive
control, and unstimulated cells served as the negative
control.
Statistical Analysis Comparisons of the distribution of T
cell frequencies were performed using Kruskal–Wallis test
(equivalent to the Wilcoxon rank sum test when comparing
two groups). Categorical comparisons, such as immune
reactivity to mycobacterial antigens by individuals within a
group, were analyzed using Fisher’s exact test. Multiple
comparisons were performed. All performed comparisons
are reported, all p values are two-sided, and all analyses
were performed using R (Version 2.1.1).
Results
Clinical and Demographic Characterization of Study
Participants Sixty-one subjects had been previously tested
for recognition of ESAT-6 and katG peptides: 26 sarcoid-
osis subjects, 24 PPD− healthy volunteers, eight subjects
with latent tuberculosis infection, and three subjects who
had undergone BCG vaccination. Of the sarcoidosis
subjects, 46% were African Americans, 42% were male,
and 58% less than or equal to 50 years of age. Of the PPD−
patients, 33% were African American, 4% were Hispanic,
38% were male and 88% less than or equal to 50 years of
age (Table I). Of the eight subjects with latent tuberculosis
infection, 25% were African American, 13% male, and
63% less than or equal to 50 years of age (Table I). None of
the sarcoidosis subjects who underwent tuberculin skin
testing were positive.
Immune Recognition of katG and ESAT-6 Peptides Reveals
a Significant Difference in the T Cell Frequencies Among
PPD−, Sarcoidosis, and PPD+ Subjects Thirteen of the 26
sarcoidosis subjects recognized katG peptide 13 compared
to none of the PPD− control subjects (p<0.0001, two-tailed
Fisher’s; Table I). Seven of the eight subjects with latent
tuberculosis infection (PPD+ 1–8) displayed immune
recognition to katG peptide. Eight of 26 sarcoidosis
subjects, one of 24 control subjects (p=0.024, two-tailed
Fisher’s), and four of eight PPD+ subjects (p=0.41, two-
tailed Fisher’s; Table I) recognized ESAT-6 peptide14.
FACS Analysis Reveals that CD4+ T Cells are Primarily
Responsible for the Sarcoidosis Response to Mycobacterial
Antigens Previous work has demonstrated the production
of IL-2 and IFN-γ by sarcoidosis PBMC in response to
ESAT-6 and katG, using ELISPOT analysis [13]. Flow
cytometry revealed that production of the Th-1 cytokines
were primarily from CD4+ T cells. While recognition by
CD4+ and CD8+ T cells was detected among some latent
tuberculosis subjects (data not shown), CD4+ T cells
responses were mainly detected among the sarcoidosis
subjects to ESAT-6. Sarcoidosis 6 demonstrated CD4+ and
CD8+ T cell responses to ESAT-6 (Fig. 1a). CD4+ T cell
recognition of katG was also detected; a representative
analysis of Sarcoidosis 10 is shown in Fig. 1b.
HLA-DR and HLA-DQ Inhibits Recognition of Mycobacterial
Peptides After the observance of mainly CD4+ T cell
responses to mycobacterial peptides, we investigated for
HLA class II restriction of immune recognition of ESAT-
peptide. Using flow cytometry, we examined the effects of
mAbs against HLA-DR, -DQ, and -DP on antigen
presentation of ESAT-6 and katG (Fig. 2). Immune
recognition of ESAT-6 peptide was partially inhibited after
blocking antigen presentation with anti-HLA-DR or anti-
HLA-DQ mAb. Monoclonal antibody against HLA-DP had
no effect.
Immune Recognition of ESAT-6 Peptide 14 is Associated
with DRB1*1101
Possessing the HLA-DRB1*1101 allele has been associated
with increased risk of susceptible disease in Caucasian and
African American sarcoidosis subjects [10]. There was no
significant difference in the frequency of the allele
DRB1*1101 among the sarcoidosis, PPD− or PPD+
groups. We assessed for HLA associations with antigen
recognition for ESAT-6 peptide 14 among the study
participants. A total of 13 subjects from all three groups
(sarcoidosis, PPD− and PPD+ due to latent MTB infection)
recognized ESAT-6 peptide 14 (Table I). Seven of the 13
subjects recognizing ESAT-6 peptide 14 possessed the
DRB1*1101 allele. In contrast, 45 subjects did not
recognize ESAT-6 peptide 14. Only five of those 45
subjects possessed the DRB1*1101 allele. The presence of
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Fig. 1 CD4+ T cells are primar-
ily responsible for the sarcoido-
sis systemic response to
mycobacterial antigens. Flow
cytometry revealed sarcoidosis
CD4+ T cells were primarily
responsible for peripheral IL-2
and interferon-γ production
when stimulated with ESAT-6
peptides. While CD8+ T cell
responses were identified by
flow cytometry among subjects
with latent tuberculosis, these
responses were rare among
sarcoidosis subjects. In one
sarcoidosis subject (Sarcoidosis
6), CD4+ and CD8+ T cell
responses were significantly
elevated above baseline (a). In
Sarcoidosis 10, stimulation with
katG peptide also induced
strong CD4+ T cells
response (b)
162 J Clin Immunol (2010) 30:157–166DRB1*1101 in seven of 13 subjects recognizing ESAT-6
peptide 14, compared to five of 45 who did not, is
significantly distinct (p=0.003, two-tailed Fisher’s), and
suggests that DRB1*1101 could be associated with antigen
presentation of ESAT-6 peptide 14.
Because the frequency of HLA alleles varies according
to ethnicity, we assessed allelic associations with immune
recognition of these mycobacterial peptides by ELISPOT
among the 22 African Americans and 35 Caucasians
subjects in this study. The lone Hispanic subject (Control
11) was omitted from the analysis due to the lack of
Hispanic subjects in the other groups. Of the African
American subjects from all three groups (sarcoidosis, PPD−
and PPD+ due to latent TB), a total of seven demonstrated
reactivity to ESAT-6 peptide 14; four of the seven
possessed the DRB1*1101 allele (Sarcoidosis 1, 6, Control
1, PPD+ 2). This is in contrast to DRB1*1101 being
present in only one (Sarcoidosis 17) of the 15 African
Americans who did not recognize ESAT-6 peptide 14 (p=
0.02, two-tailed Fisher’s; Table I, Fig. 3). Of the six
Caucasians who recognized ESAT-6 peptide 14, three
possessed DRB1*1101 (Sarcoidosis 4, 13, PPD+ 1); in
contrast, of the 29 Caucasians who did not recognize this
peptide, four possessed DRB1*1101 (Sarcoidosis 11, 16,
Control 2, 3; p=0.08, two-tailed Fisher’s; Table I, Fig. 3).
There were no allelic associations with immune recognition
of katG peptides (Table I).
Sarcoidosis T Cells Recognize ESAT-6 and katG Antigens
Presented by DRB1*1101-Expressing Antigen-Presenting
Cells The observation that monoclonal antibody against
HLA-DR partially inhibited immune responses to ESAT-6,
along with the detection of immune responses to ESAT-6
and katG in a subject homozygous for DRB1*1101 (PPD+
2) suggested that the peptides could be presented by this
allele. Using the Sweig cell line which presents using the
DRB1*1101 allele, we assessed for immune responses to
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Fig. 2 CD4+ T cell responses are partially blocked by anti-HLA-DR
and anti-HLA-DQ antibodies. Consistent with independent reports
from other labs, immune responses to ESAT-6 and katG were blocked
with monoclonal antibody against HLA-DR. Partial inhibition of
immune recognition also was observed with monoclonal antibody
against HLA-DQ. HLA-DP did not appear to have a role in ESAT-6
antigen presentation
Immune recognition of ESAT-6 by DRB1*1101
0 5 10 15 20 25 30 35
Caucasian
African-American
Caucasian
African-American
R
e
s
p
o
n
d
e
r
s
N
o
n
r
e
s
p
o
n
d
e
r
s
Number of study participants
*1101 Positive
*1101 Negative
Fig. 3 Immune recognition of
ESAT-6 peptide 14 by sarcoido-
sis subjects according to HLA-
DRB1*1101. The DRB1*1101
allele has a positive association
with risk of sarcoidosis. Of 13
subjects recognizing ESAT-6
peptide 14, seven possessed the
HLA-DRB1*1101 allele,
compared to five of 45
non-responders (p=0.0003).
Controlling for ethnicity, this
difference continued to be
significant for African
Americans, in which four of the
seven who recognized this
peptide possessed the HLA-
DRB1*1101, compared to one
of 15 who did not (p=0.02).
Among the Caucasian subjects,
there was a trend (three out of
six compared to four out of 29)
toward significance (p=0.08)
J Clin Immunol (2010) 30:157–166 163ESAT-6 and katG peptides from an expanded cell line of
Sarcoidosis 6. This subject had the MHC class II alleles
DRB1*1101/1501. The expanded cell line was generated
from PBMC stimulated with ESAT-6 peptide 14 or katG
peptide 13. The expanded ESAT-6 line demonstrated no
response to ESAT-6 peptide 14 without the presence of
Sweig cells, confirming the loss of the patient’s own
antigen-presenting cells during expansion. The addition of
Sweig cells and ESAT-6 peptide to the ESAT-6 expanded
cell line displayed a strong CD4+ IFN-γ response (Fig. 4).
The ESAT-6 expanded cell line stimulated with katG
resulted in a minimal response. The katG-expanded cell
line resulted in minimal response, after stimulation with
ESAT-6. It was noteworthy also that PBMC expanded with
katG peptide 13 also demonstrated strong CD4+ responses
to katG peptides if presented by the Sweig cells. This data
confirms that mycobacterial virulence factors ESAT-6 and
katG can be presented by the sarcoidosis susceptibility
allele, DRB1*1101.
Discussion
This study demonstrates, for the first time, that the
antigenic response in sarcoidosis is associated with HLA
type. Notably, with an HLA-DR genotype that is known to
confer increased risk for sarcoidosis in both US Caucasians
and African Americans. These are important steps in the
line of evidence supporting the hypothesis that mycobacte-
rial antigens may have a role in sarcoidosis pathogenesis by
inducing an adaptive granulomatous response in genetically
susceptible individuals. It is also probable that other HLA-
DR alleles are important in immune recognition. Studies of
associations between HLA type and recognition of ESAT-6
among tuberculosis patients have noted that individual
epitopes can be presented by diverse HLA types to human
T cells, as well as that a given HLA type can present
distinct epitopes [21, 22]. Our findings support earlier
evidence of humoral responses to mycobacterial antigens
[12, 23], and with the published literature regarding HLA
specificity for mycobacterial antigens in tuberculosis and
leprosy—two kindred granulomatous disorders [24–27].
The importance of the sarcoidosis CD4+ T cell response
has been previously reported in sarcoidosis BAL [5]. Flow
analysis confirmed that CD4+ T cells were primarily
responsible for the systemic sarcoidosis immune responses
to katG and ESAT-6 peptides. In only one of the sarcoidosis
subjects was a systemic CD8+ T cell response noted
(Fig. 1). Consistent with the vigorous immune responses
detected by ELISPOT analysis, flow cytometry revealed
that in some subjects ~1% of the systemic CD4+ T cells
recognized mycobacterial antigens (Fig. 1). In the PPD+
subjects, CD4+ and CD8+ T cell responses were noted by
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Fig. 4 HLA-DRB1*1101 presents ESAT-6 to sarcoidosis CD4+ T
cells. Intracellular cytokine staining for IFN-γ was performed on
expanded ESAT-6 and katG cell lines derived from sarcoidosis subject
6, after stimulation with either ESAT-6 peptide 14, katG peptide 13, or
SEB. No recognition was observed in the expanded cell lines alone,
demonstrating the absence of baseline IFN-γ production. Expanded
cells stimulated with ESAT-6 or katG peptide in the absence of Sweig
cells revealed minimal responses, confirming the loss of antigen-
presenting cells during expansion. Significant responses to ESAT-6
and katG were observed in the respective cell line when antigen was
presented using the DRB1*1101 expressing Sweig cell lines. Shown
are representative flow cytometry dot plots indicating percentage of
sarcoidosis CD4+ T cell responses to the different stimulation
conditions
164 J Clin Immunol (2010) 30:157–166flow cytometry (data not shown). The inhibition ESAT-6
recognition by HLA-DR and HLA-DQ but not HLA-DP is
consistent with prior reports of antigen presentation of
ESAT-6 epitopes [21, 22]. Studies of HLA associations
with tuberculosis and lepromatous antigens reveal that most
antigens are recognized in association with HLA-DR
molecules (serologically defined as HLA-DR1 to HLA-
DR10) [24–27]. HLA molecules encoded by HLA-DRB3
(HLA-DR52) and HLA-DRB4 (HLA-DR53) are also noted
to be important in presentation of antigens from Mycobac-
terium tuberculosis and Mycobacterium leprae to Th-1 cells
[27].
Our observation of an association between ESAT-6
response and HLA-DRB1*1101 is noteworthy because (1)
it is consistent with the epidemiologic data showing
increased sarcoidosis risk, and (2) it is consistent with
experimental evidence in tuberculosis and leprosy. The
observation of HLA class II associations between ESAT-6
and HLA DRB1*1101has been previously reported in
tuberculosis subjects [24]. In addition, Mustafa et al. noted
two other serologic HLA associations with this peptide
sequence: HLA-DR2 (DRB1*15, 16) and HLA-DQ2
(DQB1*0201 and DQB1*0202). Because the Sweig cell
line also presents DRB3*0202, it is possible that the
peptides are presented by this allele, or even by HLA-DQ,
although this is less likely given the lack of recognition
without the Sweig cell line. On the converse side, there
have been numerous reports of HLA associations with
sarcoidosis, one of the largest of which was conducted in
the United States, the ACCESS (A Case-Controlled
Etiologic Study of Sarcoidosis) study [19]. This study
noted a positive association between HLA-DRB1*1101 and
African American and Caucasian sarcoidosis subjects. The
observation of an association of HLA DRB1*1101 with
immune recognition of ESAT-6 peptide 14 provides a
possible immunologic and genetic basis of why this allele,
as well as others, may be important in some sarcoidosis
subjects. When assessing for the binding capacity of ESAT-
6 peptide 14 to DRB1*1101, it is consistent with moderate
to weak binding capacity [DRB1*1101 (2,358 nm) and
DRB1*1201 (4,416 nm)]. Epitopes have been identified in
peptides with binding capacities ranging between 1,000–
5,000 nm (John Sidney, personal communication). ESAT-6
peptide 14 demonstrated the strongest binding to
DRB1*0101 (2.7 nm). No significant binding of KatG
peptide 13 to HLA-DRB1*1101 was observed (25,613 nm);
binding affinities greater than 5,000 are not considered
significant (John Sidney, personal communication).
These findings do not suggest that this mycobacterial
antigen and DRB1*1101 solely are the most important
factor for the development of sarcoidosis. PBMC from the
lone PPD− subject (Control 1) that did recognize ESAT-6
peptide 14 possessed DRB1*1101, but had no evidence of
sarcoidosis. There were PBMC of sarcoidosis subjects that
did not possess the DRB1*1101 allele yet recognized
mycobacterial antigens (Sarcoidosis 2, 5, 9, for example;
Table I). Also, there were PBMC from sarcoidosis persons
which did not recognize either mycobacterial antigen
(Sarcoidosis 16–26).
Although we did not find specific HLA associations with
immune recognition of katG peptides, use of the
DRB1*1101 Sweig cell line suggests that this epitope
could be presented by DRB1*1101. This imperfect associ-
ation between the presence of the HLA class II alleles and
peptide recognition is likely due to the known degenerate
binding ability of HLA class-II restricted peptides [28].
This detection of antigen-specific immune recognition to
ESAT-6 and katG peptides contributes to the previously
reported evidence of mycobacterial antigens as a cause of
sarcoidosis. As previously reported, sarcoidosis may have
more than one etiology [29], which is influenced by the
host’s HLA type, i.e., one’s genetic predisposition to
present and recognize particular antigens than can trigger
granuloma formation. These findings suggest that in a
subset of genetically susceptible sarcoidosis patients’
immune responses to mycobacterial antigens may serve as
the initial stimulus for the development of disease. In future
studies that purport to show whether microbial antigen(s)
are associated with sarcoidosis, investigation of genetic risk
factors contributing to risk will be important, in order to
explain why some patients are found to have immune
responses to microbial antigens and others are not. Future
studies will involve longitudinal assessment of immune
reactivity to these antigens in newly diagnosed sarcoidosis
subjects, as well as studies of immune reactivity to these
antigens in matching cases and controls with respect to the
presence of HLA alleles.
Conclusions
The observation of familial clustering and racial differences
in sarcoidosis disease prevalence supports the hypothesis
that genetics have an important role in sarcoidosis patho-
genesis. A multicenter trial conducted in the United States,
ACCESS, identified an association of the MHC class II
allele, DRB1*1101 with increased susceptibility to sarcoid-
osis. CD4+ T cell responses to antigen presented in context
of MHC class II alleles is thought to be the core of
sarcoidosis pathogenesis. Here, we demonstrate that CD4+
T cells are primarily responsible for the observed systemic
responses and that recognition is associated with possession
of DRB1*1101. We also demonstrate that the mycobacterial
virulence factors, ESAT-6 and katG, when presented by
DRB1*1101 are recognized by sarcoidosis CD4+ T cells.
These findings suggest that in a subset of genetically
J Clin Immunol (2010) 30:157–166 165susceptible sarcoidosis patients’ immune responses to
mycobacterial antigens may serve as the initial stimulus
for the development of disease. Our study provides new
insights into the mechanisms underlying MHC class II
genetic associations with sarcoidosis, and the interaction of
sarcoidosis CD4+ T cells with bacterial virulence factors.
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